Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gijsbrecht F de Wit"'
Autor:
Tim Schutte, Laurien J Zeverijn, Birgit S Geurts, Gijsbrecht F de Wit, Marleen Kok, Frans L Opdam
Publikováno v:
The Oncologist.
Alpelisib is a specific oral PI3K inhibitor used combined with fulvestrant for the treatment of patients with HR+/HER2–/PIK3CA-mutated metastatic breast cancer. Adverse drug reactions with alpelisib are common, including hyperglycemia and rash. Her
Autor:
Laurien J Zeverijn, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke A M G Pisters van Roy, Lonneke Timmers, T H Ly Tran, Jolanda E de Boer, Gijsbrecht F de Wit, Birgit S Geurts, Hans Gelderblom, Henk M W Verheul, Nicole Blijlevens, A N Machteld Wymenga, Ferry A L M Eskens, Egbert F Smit, Haiko J Bloemendal, Emile E Voest
Publikováno v:
Zeverijn, L J, van Waalwijk van Doorn-Khosrovani, S B, van Roy, A A M G P, Timmers, L, Ly Tran, T H, de Boer, J E, de Wit, G F, Geurts, B S, Gelderblom, H, Verheul, H M W, Blijlevens, N, Wymenga, A N M, Eskens, F A L M, Smit, E F, Bloemendal, H J & Voest, E E 2022, ' Harmonising patient-access programmes : the Dutch DRUG Access Protocol platform ', The Lancet Oncology, vol. 23, no. 2, pp. 198-201 . https://doi.org/10.1016/S1470-2045(21)00707-5
The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group
Lancet Oncology, 23, 198-201
Lancet Oncology, 23, 2, pp. 198-201
The Lancet Oncology, 23(2), 198-201. Lancet Publishing Group
Lancet Oncology, 23, 198-201
Lancet Oncology, 23, 2, pp. 198-201
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e79f0dca3475d812d212a606ef4951
https://research.vumc.nl/en/publications/3b1be06b-d5da-4ce0-8d91-ec8744ecd5cb
https://research.vumc.nl/en/publications/3b1be06b-d5da-4ce0-8d91-ec8744ecd5cb